Inspire Medical ( (INSP) ) has released its Q2 earnings. Here is a breakdown of the information Inspire Medical presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inspire Medical Systems, Inc. is a medical technology company that specializes in developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea. The company’s proprietary Inspire therapy is the first FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea.
Inspire Medical Systems recently announced its financial results for the second quarter of 2025, highlighting a revenue increase to $217.1 million, an 11% rise compared to the same period last year. The company also reported a gross margin of 84.0% and an adjusted net income of $13.3 million, despite a net loss of $3.6 million. The launch of the Inspire V neurostimulation system in the U.S. was a significant milestone, although the commercial rollout is progressing slower than anticipated.
Key financial metrics from the second quarter include a 10% increase in U.S. revenue and a 23% rise in international revenue. Operating expenses grew by 15% due to investments in sales expansion and marketing, alongside a one-time stock-based compensation charge. The company faced an operating loss of $3.3 million, contrasting with the previous year’s operating income of $5.1 million. Adjusted EBITDA improved to $44.1 million from $38.7 million in the prior year.
Looking ahead, Inspire Medical Systems anticipates full-year 2025 revenue to range between $900 million and $910 million, reflecting a growth of 12% to 13% over 2024. The company remains optimistic about overcoming current operational challenges and is committed to delivering strong patient outcomes and driving profitable growth.